Phase 12 Study of Single-Dose SP-101 Gene Therapy Delivered by Nebulizer to Treat Cystic Fibrosis in Adults Not Eligible for CFTR Modulators
Led by Spirovant Sciences, Inc. · Updated on 2024-11-25
15
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SP-101, an investigational gene therapy, in adults with cystic fibrosis CF who cannot use or tolerate CFTR modulator therapy. This Phase 12, first-in-human study aims to assess the safety, how the body processes the drug, and its biological effects with varying doses. The trial is open-label and conducted at multiple centers.
Participants receive a single inhaled dose of SP-101 combined with doxorubicin at different dose levels. The study includes three groups Dose 1, Dose 2, and a selected dose expansion group. Each participant will receive only one inhalation treatment during the trial.
During the study, researchers will monitor participants for adverse events over 52 weeks to evaluate safety. They will also measure how the drug behaves in the body and its impact. Participants will have regular assessments including lung function tests and oxygen levels. The trial lasts about a year, during which participants will be closely observed and evaluated.
CONDITIONS
Brief Title
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
Research Team
S
Spirovant.ClinicalTrials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
SP-101 Inhaled Gene Therapy (with Doxorubicin)
Current Guideline-Recommended CFTR Modulator Therapy
What it is
A novel inhaled investigational gene therapy using an adeno-associated virus vector (SP-101) delivered in combination with doxorubicin to introduce functional CFTR gene copies to airway cells.
An orally administered or modulator therapy targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein to improve its function for patients with eligible CF mutations.
Role in trial
All participants in the study receive SP-101 with doxorubicin at escalating or expanded single inhaled doses.
Not evaluated in this study arm, but represents the established standard therapy for most CF patients outside interventional trials.
Primary use
Being studied to determine safety and how the body responds to single inhaled doses of the gene therapy in adults with cystic fibrosis.
Recommended as ongoing therapy for eligible individuals to improve lung function and reduce complications of the disease.
How it is given or performed
Delivered as a single inhaled dose of SP-101 with doxorubicin using a nebulizer device under direct supervision in a clinical setting as part of escalating-dose cohorts.
Taken by mouth as an ongoing daily tablet or granule formulation at home, according to current guideline recommendations.
Evidence status
Evidence is currently limited to early-phase clinical and preclinical research; the trial aims to assess safety and initial biological effects in humans.
Supported by multiple clinical trials and long-term studies showing improvements in lung function, reduction in exacerbations, and improved quality of life for eligible genotypes.
Important limitations
Clinical experience in humans is limited to ongoing initial studies; efficacy and long-term safety remain unknown. The trial studies single-dose administration and cannot assess chronic or repeated use.
CFTR modulator therapy is only effective in patients with specific CFTR gene mutations; some individuals may be ineligible or have a suboptimal response due to mutation type or medication tolerance.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 65Years
All Genders
Eligibility Criteria
You may qualify if you...
Males or females aged 18 to 65 years at Screening Visit, inclusive
Diagnosis of cystic fibrosis
ppFEV1 value between 50-100% (inclusive)
Resting oxygen saturation of 94% or higher on room air by pulse oximetry
Clinically stable cystic fibrosis disease not requiring new interventional treatment within 3 months prior to Screening
You will not qualify if you...
Any change in established pulmonary treatment (including antibiotics) within 28 days prior to Screening, except inhaled beta-agonists within 2 weeks prior
Clinically significant hemoptysis (>50 mL or 1/4 cup per day) within 12 weeks prior to dosing
Lung infection with Mycobacterium abscessus causing rapid decline
Active treatment for lung infection with Burkholderia cenocepacia or Burkholderia dolosa
History of solid organ or blood transplantation
History of clinically significant cirrhosis with or without portal hypertension
History of pulmonary hypertension
History of cardiotoxicity, coronary artery disease, or cardiomyopathy
Current active fungal infection, acute blood, lung, or bladder infection, significant liver or kidney dysfunction, or viral infection requiring new therapy within 30 days prior
History of allergic bronchopulmonary aspergillosis (ABPA)
Uncontrolled diabetes with hemoglobin A1c >9% at Screening
Clinically significant lab abnormalities at Screening
Any medical condition or lab result interfering with safe study completion
Receipt of any investigational products within 30 days or 5 half-lives prior to Screening
Prior gene therapy
Known sensitivity to SP-101, doxorubicin, or excipients
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single dose with follow-up up to 52 weeks
Participants receive a single inhaled dose of SP-101 and doxorubicin to evaluate safety and pharmacokinetics.
1 treatment visit and multiple follow-up visits over 52 weeks
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Study of Inflammatory Lung Diseases Including Asthma, COPD, Bronchiectasis, Cystic Fibrosis, PCD, and ILD to Understand Patient Characteristics and Improve Personalized Treatment
Phase 12 Study of Single-Dose SP-101 Gene Therapy Delivered by Nebulizer to Treat Cystic Fibrosis in Adults Not Eligible for CFTR Modulators
Research Study to Support New Cystic Fibrosis Treatments for People Not Using CFTR Modulators
Phase 1 Study of Inhaled KB407 for Treating Cystic Fibrosis in Adults
Usability and Safety Study of MuCopilot Mobile App for Monitoring Cystic Fibrosis at Home
Advancing Telemedicine in Pulmonology Using Smartphone-Based Acoustic Waveform Respiratory Evaluation to Diagnose Asthma, COPD, and Other Airway Diseases
Study of Beta-cell Response to Incretin Hormones GLP-1 and GIP in Adults with Cystic Fibrosis and Pancreatic Insufficiency
Canadian Observational Study on the Long-Term Effects of CFTR Modulator Therapies in People with Cystic Fibrosis
Rethinking Care Organization for Cystic Fibrosis in France with Highly Effective Modulator Treatments
Study of Women With Cystic Fibrosis Using Elexacaftor-tezacaftor-ivacaftor During Pregnancy and Breastfeeding and Their Children
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
SP-101, A Novel Adeno-Associated Virus Gene Therapy for the Treatment of Cystic Fibrosis, Mediates Functional Correction of Primary Human Airway Epithelia From Donors with Cystic Fibrosis.
Katherine J D A Excoffon, Shen Lin, Poornima Kotha Lakshmi Narayan...
Inhalation of SP-101 Followed by Inhaled Doxorubicin Results in Robust and Durable hCFTRΔR Transgene Expression in the Airways of Wild-Type and Cystic Fibrosis Ferrets.
Katherine J D A Excoffon, Mark D Smith, Lillian Falese...